EXELED HOLDINGS IN COM USD0.01 (OTCMKTS:ELED) Refutes Acquisition Talk

EXELED HOLDINGS IN COM USD0.01 (OTCMKTS:ELED)

EXELED HOLDINGS IN COM USD0.01 (OTCMKTS:ELED) has refuted claims that it is in discussions with a potential acquirer. Further, in a press release, the company has reiterated plans to continue operating as a standalone company. The management team has also stressed that there have been no material changes in the company’s business or long term prospects.

However, the market is buying on the rumor and shares of ELED are up over 25% in morning trading.

ExeLED Business Overview

EXELED HOLDINGS IN COM USD0.01 (OTCMKTS:ELED) is a diversified holding company focused on acquiring complementary companies with operations around LED lighting solutions. The company’s wholly owned subsidiary Energie LLC, located in Colorado, targets the multibillion-dollar North American lighting market.

To become a leading provider of advanced lighting solutions is EXELED HOLDINGS IN COM USD0.01 (OTCMKTS:ELED), core objective. The company intends to grow, innovate, and fully capture the rapidly growing lighting market opportunities. ExeLED has already sold some of its products to education and commercial enterprises. Five European manufacturers and one in Taiwan currently produce the company’s products.

“Our Advisory Team intends to provide access to the best resources to apply LED technology for our subsidiaries. We also intend to provide buying contracts with LED component manufacturers to control cost while staying at the leading edge of the technology,” ExeLED in a statement.

EXELED HOLDINGS IN COM USD0.01 (OTCMKTS:ELED) is planning to lead the LED sector that is continually expanding. The market is currently worth $29 billion and could be worth $33 billion by year-end.

Q1 Financial Results

For the first three months of the year, EXELED HOLDINGS IN COM USD0.01 (OTCMKTS:ELED) posted a net loss of (-$816,917) a drop from a net loss of (-$890,586) reported for the corresponding quarter last year. Revenues in the quarter dropped to $37,275 from highs of $98,555 reported in Q1 2016. Research and development expenses in the quarter totaled $68,604 compared to $72,991 as of Q1 2016.

Sales and marketing expenses in the first quarter totaled $999, compared to $12,715 reported in Q1 2016. EXELED HOLDINGS IN COM USD0.01 (OTCMKTS:ELED) exited the quarter with cash and cash equivalent of $53,398 compared to $5, 454 as of. last year

Prior to EXELED HOLDINGS IN COM USD0.01 (OTCMKTS:ELED) refuting claims about being acquired, the company had been dead silent in the market. However, the stock continues to elicit renewed interest from investors in the wake of acquisition talk. The fact that company was able to deliver outstanding returns without any evidence to collaborate the same also appears to be fuelling interest from traders.

EXELED HOLDINGS IN COM USD0.01 (OTCMKTS:ELED) stock was down by 5.95% in Friday’s trading session ending the week at $0.00790 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ELED and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Greengro Technologies Inc. (OTCMKTS:GRNH) Forms Joint Venture

Greengro Technologies Inc. (OTCMKTS:GRNH)

Greengro Technologies Inc. (OTCMKTS:GRNH) has signed an agreement for the formation of a joint venture with Maqsood Rehman, a renowned plant geneticist. The joint venture is for the development, patenting, and licensing of various cannabis strains.

Joint Venture Formation

Greengro Technologies Inc. (OTCMKTS:GRNH)’s subsidiary, GenoBreeding will own 60% of the Joint Venture with the remaining 40% going to Mr. Rehman. The signing of the agreement comes on the heels of GenoBreeding signing an agreement for its first customer, igot420.

The Joint Venture’s business plan will rely on advanced technologies including breeding methods and genome sequencing to come up with cannabis strains.

“The Company is confident its proprietary combination and utilization of these tools, under the painstaking direction of one of the nation’s best-qualified plant geneticists, will yield valuable new strains of cannabis and push the edge of the technology to new levels of science. His team includes two master cannabis growers and a molecular genetics and data development scientist,” said Greengro Technologies Inc. (OTCMKTS:GRNH) in a statement.

GenoBreeding will patent any strains that are created as a result of the partnership. In addition to selling cannabis strains, the company also plans to license them to other companies such as igot420.

The company’s commercialization plan will target growers, producers, and dispensaries looking to develop marijuana strains. Greengro Technologies Inc. (OTCMKTS:GRNH) also plans to target biotech firms planning to conduct cannabis-related clinical research trials.

Rehman Appointment

In addition to forming a joint venture, GreenGro Technologies has appointed Dr. Rehman as the Chief Operating Officer. He joins the company with vast experience and a diverse background in working with large public and private companies in the field of genetics.

Dr. Rehman will lead Greengro Technologies Inc. (OTCMKTS:GRNH) Gala Global development team. The team is currently commercializing digital plant cloning incubators from Controlled Environment Genomics.

“We welcome Dr. Rehman as he brings with him a diverse background of working with large public and private companies in the field of genetics and the commercialization of genetically modified crops for a wide variety of uses,” said Gala Global CEO, Timothy Madden.

$4 Million Financing

Separately, the provider of eco-friendly green horticulture technologies has secured $4 million in financing. The money is to be used to build a second igot420 dispensary in Cathedral City. Greengro Technologies Inc. (OTCMKTS:GRNH) has already received $2 million of the financing with the remaining $2 million set to be drawn pending project advancement.

Greengro Technologies Inc. (OTCMKTS:GRNH) stock was up by 0.51% in Friday’s trading session to end the week at $0.0495 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GRNH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

FalconStor Software, Inc. (NASDAQ:FALC) Names Oseth As President & CEO

FalconStor Software, Inc. (NASDAQ:FALC) 

FalconStor Software, Inc. (NASDAQ:FALC) has appointed Todd Oseth as the company’s President and Chief Executive Officer as of July 1, 2017. FalconStor Software specializes in the production of storage software. The company also announced the resignation of its former President and Chief Executive Officer Gary Quinn that will take effect on July 1, 2017.

Mr. Oseth will be tasked with delivering highly profitable business growth by directly working with the company’s partners, customers, investors, and employees in pursuing the company’s strategic objectives. Before joining FalconStor Software, Inc. (NASDAQ:FALC) Oseth worked as the President and Chief Executive Officer at Intermap Technologies where he is credited with initiating and leading a company transformation and making it one of the leading providers of geospatial solutions. Previously, he held executive positions in Ramtron, Sony, EMC, and McDATA.

In a statement, Oseth said the company has a strong foundation in data mobility and protection and it is focused on lowering the cost of storage by use of its public cloud services. Oseth said he will use his first hundred days to meet with the company’s customers and partners globally in a bid to ensure that the company meets both their current and future needs while maintaining focus on the company’s internal operations.

Martin Hale, a member of FalconStor Software, Inc. (NASDAQ:FALC)’s Board of Directors lauded Gary Quinn for his outstanding services to the company both in terms of contribution and leadership during his reign as the company’s President and Chief Executive Officer. Hale added that the company has a bright future in Todd as the new President and Chief Executive Officer of the company. He added that Todd is the right person to steer the company to a profitable path.

In the Thursday trading session, FalconStor Software, Inc. (NASDAQ:FALC) reported a +53.78% or +0.133 to trade at $0.380.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $FALC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

East Hill Management Calls For liquidation Of Aviragen Therapeutics Inc. (NASDAQ:AVIR)

Aviragen Therapeutics Inc. (NASDAQ:AVIR)

Aviragen Therapeutics Inc. (NASDAQ:AVIR) should abandon all its strategic plans according to East Hill Management. The investment firm, in a filing, states that the company should wind down its business and liquidate. The sentiments come after the company posted a first-quarter net loss of (-$4.4) million.

Strategic Review Process

Following the dismal performance in the first quarter, the biopharmaceutical company confirmed it was actively involved in a strategic review process. The process seeks to evaluate a wide range of alternatives that include a business sale, merger, and/or a licensing of clinical stage programs.

“We are expeditiously working with our Board and financial advisors to consider a wide range of strategic alternatives in a process that is intended to enhance shareholder value both in the near and long term. We remain confident about the overall value proposition of Aviragen based on our fuller review of data from our clinical trials that reported topline results earlier this year, our ongoing Phase 2 study of BTA074 and our solid financial position,” said CEO Joseph Patti in a recent earnings call

Aviragen Therapeutics Inc. (NASDAQ:AVIR) is also exploring acquisitions as well as transactions that have the potential to bolster its pipeline. However, it appears that East Hill Management, a major shareholder, is not buying into the company’s restructuring push.

Q1 Financial Results

It is still unclear how the investment firm plans to generate value by winding down Aviragen Therapeutics Inc. (NASDAQ:AVIR) operations. The company is currently undertaking a Phase 2 trial of BTA074, a candidate drug for the treatment of condyloma. Vapendavir is another novel treatment that the company is working on with key opinion leaders for the treatment of Asthma.

Doubts about Aviragen Therapeutics Inc. (NASDAQ:AVIR)’s future comes on the heels of a disappointing first quarter where revenue was down to $4.9 million from $5.3 million as of Q1 2016. Aviragen attributes the drop to a decrease in Relenza royalties.

Research and development expenses dropped to $6.8 million compared to $8.5 million reported a year ago. Lower employee costs and professional fees led to a drop of General and Administrative expenses to $1.8 million from $2.3 million. Aviragen Therapeutics Inc. (NASDAQ:AVIR) ended the quarter with cash and cash equivalent of $37.6 million.

Aviragen Therapeutics Inc. (NASDAQ:AVIR) stock was up by 20.83% in Thursday’s trading session to end the day at $0.580 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVIR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

OvaScience Inc (NASDAQ:OVAS) Welcomes New CEO

OvaScience Inc (NASDAQ:OVAS)

OvaScience Inc (NASDAQ:OVAS) shares are up over 13% on volumes in excess of four times their normal average. Waltham, MA-based OvaScience Inc (NASDAQ:OVAS) today announced that Christopher Kroeger, M.D., M.B.A., has been appointed Chief Executive Officer. The appointment will take effect on September 1, 2017. Dr. Kroeger is reported to possess extensive experience leading, building and advising development-stage therapeutic and medical device companies. Dr. Kroeger brings a strong clinical and research background as a practicing physician and scientist. Upon Dr. Kroeger’s transition to OvaScience Inc (NASDAQ:OVAS), Michelle Dipp, M.D., Ph.D., Co-Founder and Executive Chairman of OvaScience plans to step down as Executive Chairman and will serve as an advisor to the Company.

Terms of employment include stock options. OvaScience Inc (NASDAQ:OVAS)’s Compensation Committee approved the terms of compensation on June 21, 2017. Dr. Kroeger’s compensation consists of options to purchase up to 1,783,106 shares of common stock. The options are exercisable at $1.46 per share, equal to the closing price per share of OvaScience’s common stock as of June 21, 2017. The stock options vest over about 5 years and 7 months, subject to continued service with OvaScience Inc (NASDAQ:OVAS) through the applicable vesting dates.

OvaScience, Inc. (NASDAQ: OVAS) discovers, develops and commercializes new fertility treatments. OvaScience treatments are based on their proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC℠) cells – immature egg cells found inside the protective ovarian lining. OvaScience is developing OvaTure℠, a potential next-generation in vitro fertilization (IVF) treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections and OvaPrime℠, which could increase a woman’s egg reserve. Importantly, this treatment is unavailable inside the United States.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OVAS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) Gaining

DelMar Pharmaceuticals Inc (NASDAQ:DMPI)

Biotechnology firm DelMar Pharmaceuticals Inc (NASDAQ:DMPI), based in Vancouver, Canada, shares are rising on large volumes. DMPI shares closed yesterday at $1.85 and gapped up to open at $1.95 before reaching an inter-day high of $2.73. As of 12:30 PM EST, DMPI shares are up over 22% at $2.27. Trading volume has increased to an extraordinary level when compared to the listed 30-day, daily average trading volume as over 2.1 million shares have traded hands by lunch. DMPI has a 52-week high of $9.90 and a 52-week low of $1.66.

Investor attention seems to have been heightened after DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) today announced that it will present an abstract at the 12th Meeting of the European Association of Neuro-Oncology. The presentation will take place in Mannheim, Germany from October 12 – 16, 2016. DelMar’s presentation will center around their lead drug candidate VAL-083 and how it attacks cancer cells utilizing methods that separate it from other chemotherapy treatments for glioblastoma multiforme (GBM) which is the most common and aggressive form of brain cancer. Specifically, DelMar will present data supporting the potential of VAL-083 to treat patients whose tumors exhibit resistance to existing chemotherapies used in the treatment of GBM.

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI)’s VAL-083 is a “first-in-class,” small-molecule chemotherapeutic. In more than 40 Phase 1 and 2 clinical studies, VAL-083 demonstrated clinical activity against a range of cancers. Importantly for investors, VAL-083 has received an orphan drug designation (ODD) in Europe for the treatment of malignant gliomas; and the U.S. FDA Office of Orphan Products has granted an orphan designation to VAL-083 for the treatment of glioma, medulloblastoma and ovarian cancer.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AMCN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Cobalt International Energy, Inc. (NYSE:CIE) Reverse Stock Split

Cobalt International Energy, Inc. (NYSE:CIE)

Cobalt International Energy, Inc. (NYSE:CIE) has carried out a 1:5 reverse stock split as part of an effort that seeks to bolster the stock’s share price. Shareholders had initially proposed a 5-for-15 reverse stock split.

NYSE Delisting Notice

Reverse stock splits sometimes undermine the perceived value of a stock and drive share price lower. During the recent earnings call Cobalt International Energy, Inc. (NYSE:CIE) CEO, Tum Cutt, reiterated his concern about the impact of the proposed reverse stock split.

“Obviously, we prefer to kind of demonstrate that we actually have the value in there for our shareholder. For our shares just to trade higher than they are today,” said Mr. Cutt.

The reverse stock split comes on the heels of the New York Stock Exchange issuing a warning about the company’s dwindling stock price. The stock’s drop below the $1 a share mark prompted a delisting notice from the exchange. However, the stock has bounced back even though it continues to trade at multi-year lows.

Financial Woes

Crude prices doping below the $50 a barrel mark continues to plunge Cobalt International sentiments among investors. A major point of concern is that a further drop in oil prices will make it hard for the company to generate significant returns from its development projects.

Cobalt International Energy, Inc. (NYSE:CIE) financial woes stem from the fact that it is spending too much money on development projects than it is generating from existing operations. The company has enough cash to last through mid-2018, after which it could find it hard to meet its financial obligations. The company needs crude prices to bounce back from current levels if efforts on working projects are to pay off and avoid a worse fate.

Reducing debt load is one of Cobalt International Energy, Inc. (NYSE:CIE) objectives as it continues to explore ways of staying afloat. Over the past six months, the energy company has trimmed its debt load by $339.2 million. Regulatory filings indicate that the company did issue $32.14 million of 7.750% second lien 2023 senior secured notes, in exchange of $60.932 million in 2024 convertible senior notes.

Cobalt International Energy, Inc. (NYSE:CIE) stock was down by 12.12% in Wednesday’s trading session to end the day at $2.61 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CIE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Continues Higher

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has had two days of substantial gains and seems to have triggered a sell program as shares met significant resistance at $2.85. Last Thursday, Friday, and Monday BDSI shares had a tough time breaking above $2.30 then yesterday shares moved up steadily only to meet some mild resistance at $2.60. Today shares gapped up to open at $2.75 and quickly climbed to $2.85 by mid-day but, apparently, strong selling kicked in and BDSI was unable to sustain any moves above $2.85 and closed today at $2.75. Volumes were heavy. Over 2.2 million shares of BDSI traded today or about three times their 30-day, daily average trading volume of 613,500.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s development strategy focuses on the utilization of the FDA’s 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.

Today, upward movement was likely helped along by the company’s announcement that it has signed an agreement with CVS/Caremark extending access to both BELBUCA® (buprenorphine) buccal film (CIII) and BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) through 2020. The agreement is important as CVS/Caremark represents a significant portion of the covered lives in the United States. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) reacquired BELBUCA from Endo Pharmaceuticals in January 2017 and subsequently relaunched the product. Prescription sales for BELBUCA reached their highest point in May 2017 since the product was launched by Endo in early 2016 and continues to grow in June. Weekly sales for BELBUCA for the week ending June 9, 2017 (1,657 prescriptions) exceeded the previous peak from December 2016 for the first time according to data from Symphony Health.

Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have performed well over every timeframe. In the past week, BDSI shares gained over 14%, they are up over 6% for the month, up over 48% YTD, and up over 10% for the year. Seven investment firms follow BDSI shares. Six rate them as a “Strong Buy” and one rates them as “Hold” Their consensus price target is $4.00.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BDSI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Fourth Day in a Row of Gains for AirMedia Group Inc (ADR) (NASDAQ:AMCN)

AirMedia Group Inc (ADR) (NASDAQ:AMCN)

Shares of China-based AirMedia Group Inc (ADR) (NASDAQ:AMCN) are up for the fourth day in a row. Last Friday, AMCN shares established a new 52-week low and closed at $1.40 and, with 45 minutes left in today’s trading session, are hovering around $2.35. Today’s volumes have been this week’s heaviest so far. Over 3.1 million shares have traded hands and the listed 30-day, daily average volume for shares of AMCN is just 328,670.

AirMedia Group Inc (ADR) (NASDAQ:AMCN) sells advertising on its air travel advertising network. AirMedia also holds concession rights to install and operate Wi-Fi systems on trains, administered by over eight regional railway administrative bureaus in China, and on various long-haul buses in China. AirMedia has access to 71,900 airplane digital television screens on over five airlines, including Air China, China Eastern Airlines, China Southern Airlines, Shanghai Airlines and Xiamen Airlines. It also holds concession rights to operate the advertising media platforms at Sinopec gas stations across China.

While AMCN shares have gained over 27% during the past week, they have lost over 22% YTD, and are down over 50% for the year. However, interestingly, AMCN shares have been trading at a discount to their cash per share figure for some time. Financial data providers have AMCN’s cash/share value listed at $3.90. A review of historical prices shows that AMCN shares have traded over $3.50 just three times since last July. However investors should be aware that AirMedia Group Inc (ADR) (NASDAQ:AMCN) is based in China and some observers sometimes doubt the veracity of financial statements that lack a similar oversight structure as their American counterparts. Its also relevant to observe that sales have been steadily declining since 2012 when the company posted a figure over $286 million only to post a figure of $50.2 million in 2015. Similarly, earnings losses have widened over the years. In 2013, shareholders lost (-$0.48) per share and that loss expanded to (-$1.16) by 2015.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AMCN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Gains in Dataram Corp (NASDAQ:DRAM) a Head Fake?

Dataram Corp (NASDAQ:DRAM)

Princeton, NJ-based Dataram Corp (NASDAQ:DRAM) shares are up over 8% in morning trading. DRAM shares closed Tuesday at $2.79 and gapped up this morning to open at $3.15 before retreating. Shares are now trading around $3.00. There has been a massive increase in volume. Dataram has a 30-day, daily average trading volume of 87,000 but today, by 12:30 PM EST, over 2.2 million shares have traded hands.

Dataram and U.S. Gold Corp completed a merger late last month. The combined company trades under the ticker DRAM and news for each of the companies is often listed under the pre-merger names.

The catalyst for the shares’ move higher is the staking of 102 additional claims for the Keystone Project located on the prolific Cortez Trend. The Keystone Project now consists of 479 unpatented lode-mining claims, including the 102 additional and newly-staked claims on the east and southeastern portions of the property in Eureka County, Nevada.

Dave Mathewson, US Gold Corp’s Vice President and Head of Nevada Exploration, stated “I have been on and off the Keystone property for more than 30 years and I believe Keystone represents one of the best exploration opportunities in Nevada. This is the first time in the history of the district that a single company has consolidated the entire district, and US Gold Corp. will certainly benefit from being able to design an exploration program based exclusively on geology instead of claim boundaries.”

DRAM shares have been on a downward trend since early 2011. Earlier this month DRAM shares established a new 52-week, and lifetime, low share price of $2.55. Accordingly, performance has been disappointing for shareholders. YTD DRAM shares are down over 68%, and down over 71% for the year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRAM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.